JP2025507416A - 解剖学的及び機能的な網膜萎縮の治療 - Google Patents
解剖学的及び機能的な網膜萎縮の治療 Download PDFInfo
- Publication number
- JP2025507416A JP2025507416A JP2024548656A JP2024548656A JP2025507416A JP 2025507416 A JP2025507416 A JP 2025507416A JP 2024548656 A JP2024548656 A JP 2024548656A JP 2024548656 A JP2024548656 A JP 2024548656A JP 2025507416 A JP2025507416 A JP 2025507416A
- Authority
- JP
- Japan
- Prior art keywords
- pharma
- retinal
- eye
- disease
- therapeutically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/348—Cannabaceae
- A61K36/3482—Cannabis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2022900318A AU2022900318A0 (en) | 2022-02-15 | Treatment of anti-vegf refractory ophthalmic retinal eye conditions | |
| AU2022900318 | 2022-02-15 | ||
| PCT/AU2023/050103 WO2023154980A1 (en) | 2022-02-15 | 2023-02-15 | Treatment of anatomical and functional retinal atrophies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025507416A true JP2025507416A (ja) | 2025-03-18 |
| JP2025507416A5 JP2025507416A5 (enExample) | 2026-02-24 |
Family
ID=87577221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024548656A Pending JP2025507416A (ja) | 2022-02-15 | 2023-02-15 | 解剖学的及び機能的な網膜萎縮の治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250387410A1 (enExample) |
| EP (1) | EP4479061A4 (enExample) |
| JP (1) | JP2025507416A (enExample) |
| CN (1) | CN119031918A (enExample) |
| AU (1) | AU2023221950A1 (enExample) |
| WO (1) | WO2023154980A1 (enExample) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019207515B2 (en) * | 2018-01-10 | 2024-11-14 | Eye Co Pty Ltd | Medical device and pharmaceutical composition for treatment of an eye disease or condition |
| PL3684370T3 (pl) * | 2018-02-26 | 2025-07-28 | Eye Co Pty Ltd. | Kompozycja i leczenie zaniku geograficznego fludrokortyzonem |
-
2023
- 2023-02-15 US US18/837,905 patent/US20250387410A1/en active Pending
- 2023-02-15 CN CN202380025844.9A patent/CN119031918A/zh active Pending
- 2023-02-15 WO PCT/AU2023/050103 patent/WO2023154980A1/en not_active Ceased
- 2023-02-15 EP EP23755583.4A patent/EP4479061A4/en active Pending
- 2023-02-15 AU AU2023221950A patent/AU2023221950A1/en active Pending
- 2023-02-15 JP JP2024548656A patent/JP2025507416A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN119031918A (zh) | 2024-11-26 |
| AU2023221950A1 (en) | 2024-09-19 |
| EP4479061A4 (en) | 2026-01-07 |
| WO2023154980A1 (en) | 2023-08-24 |
| US20250387410A1 (en) | 2025-12-25 |
| EP4479061A1 (en) | 2024-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Arevalo et al. | Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months | |
| Souied et al. | Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study | |
| EP3441069B1 (en) | Treatment of diabetic retinopathy using pharmaceutical agents that eliminate senescent cells | |
| JP2025069279A (ja) | 血管形成眼障害を処置するためのvegfアンタゴニストの使用 | |
| Arevalo et al. | Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: pilot study of the Pan-American Collaborative Retina Study Group | |
| US11865123B2 (en) | Methods of inhibiting pathological angiogenesis | |
| Mayer et al. | Dexamethasone implant as an effective treatment option for macular edema due to Irvine-Gass syndrome | |
| Verma et al. | A prospective controlled trial to evaluate the adjunctive role of posterior subtenon triamcinolone in the treatment of diffuse diabetic macular edema | |
| CN115697333A (zh) | 包含阿西替尼的组合物和治疗眼部疾病的方法 | |
| CN110114066B (zh) | 含沙丁胺醇的眼科药物 | |
| US20220331345A1 (en) | Methods of Treating Retinal Vasculopathies | |
| Mirshahi et al. | Efficacy of adjuvant topical timolol–dorzolamide with intravitreal bevacizumab injection in diabetic macular edema: A contralateral eye study | |
| Pizzimenti et al. | Central serous chorioretinopathy after epidural steroid injection | |
| Nghiem-Buffet et al. | Intravitreal ranibizumab and/or dexamethasone implant for macular edema secondary to retinal vein occlusion | |
| TW201904610A (zh) | 用於治療新生血管型青光眼之非抗體vegf拮抗劑 | |
| JP2025507416A (ja) | 解剖学的及び機能的な網膜萎縮の治療 | |
| Singh et al. | Cho | |
| Krasniqi et al. | Anti–VEGF Treatment in Macular Edema Due to Retinal Vein Occlusion | |
| Senturk et al. | Retinal sensitivity improvement after intravitreal triamcinolone acetonide injection for macular edema secondary to branch retinal vein occlusion | |
| Hong et al. | Phase 1B study of the safety and tolerability of the mineralocorticoid fludrocortisone acetate in patients with geographical atrophy | |
| Kasetty et al. | Complications, compliance, and 3-year outcomes after endolaserless vitrectomy with aflibercept monotherapy for proliferative diabetic retinopathy-related vitreous hemorrhage | |
| US20250025452A1 (en) | Compositions comprising axitinib and methods of treating ocular disorders | |
| Pacella | Treatment chronic macular edema in Vogt-Koyanagi Harada syndrome with dexamethasone intravitreal implant: description of three case | |
| Chan et al. | Intraocular pressure changes after repeated intravitreal antivascular endothelial growth factor injections in patients with neovascular age-related macular degeneration with or without glaucoma | |
| Ahmad et al. | Comparison of intravitreal Diclofenac-Sodium Versus intravitreal Triamcinolone in diabetic Macular Edema |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260213 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260213 |